Search clinical trials for: Ropinirole immediate release (IR)

Total 262 results

Pfizer

Completed

A Sub Study to Evaluate the Study Medication (Etrasimod) Using Wearable Sensors in Healthy Participants

Healthy Participants

Belgium
GlaxoSmithKline

Completed

Converting From Ropinirole Immediate Release (IR) To Ropinirole Controlled-Release for RLS (Restless Legs Syndrome)

Restless Legs Syndrome | Restless Legs Syndrome (RLS)

United States
GlaxoSmithKline

Terminated

Clinical Evaluation of Ropinirole IR (Immediate Release) Tablets in Patients Who Are Diagnosed With Symptomatic Restless Legs Syndrome (RLS) Associated With Chronic Kidney Disease (CKD) Managed With Haemodialysis (Including Haemofiltration and Haemodiafiltration)

Restless Legs Syndrome

Japan
Bayer

Completed

A Study to Learn How the Study Treatment BAY3283142 Taken as Single Dose by Mouth Moves Into, Through, and Out of the Body, How Safe it is, and How it Affects the Body in Participants With Reduced Kidney Function Compared to Participants With Normal Kidney Function of Similar Age, Gender, and Weight

Renal Impairment | Chronic Kidney Disease | Healthy Volunteers

Germany
GlaxoSmithKline

Completed

A Comparison of Ropinirole Immediate Release With Ropinirole Prolonged Release in Patients With Advanced Parkinson's

Parkinson Disease

Spain, France, Bulgaria, United Kingdom, Germany, Hungary, Russian Federation, South Africa, Italy, Canada, Czechia, Poland, Romania, Ukraine
Alexion

Recruiting

A Study to Investigate the Pharmacokinetic Profile of ALXN2050 Modified Release Prototype Formulations and Immediate Release Reference Tablet in Healthy Adult Participants

Healthy Participants

United Kingdom
GlaxoSmithKline

Completed

Clinical Evaluation of Ropinirole Prolonged Release/Extended Release (PR/XR) Tablet for Adjunctive Therapy to L-dopa in Subjects With Advanced Parkinson's Disease

Parkinson Disease

Japan
AstraZeneca

Withdrawn

A Study to Compare the Pharmacokinetics of Different Formulations of AZD9977 and the Influence of Food in Healthy Male Subjects

Healthy Male Subjects | Pharmacokinetics | Safety | Food Effect

United Kingdom
GlaxoSmithKline

Completed

Ropinirole Tablets In Young Patients With Restless Legs Syndrome

Restless Legs Syndrome

United States, Belgium, France
Elcelyx Therapeutics, Inc.

Completed

Assessing the PK and Effect on Glucose and GI Hormone Concentrations of Metformin Delayed-Release in Subjects With T2DM

Type 2 Diabetes Mellitus

United States
Johnson & Johnson Pharmaceutical Research & Development...
Grünenthal GmbH

Completed

Study on the Safety and Effectiveness of Switching Between Two Forms of Tapentadol in Patients With Chronic Low Back Pain

Low Back Pain
Hangzhou Highlightll Pharmaceutical Co., Ltd

Completed

Evaluation of TLL-018 Extended and Immediate Release Formulation for Bioequivalence Testing in Healthy Chinese Subjects

Atopic Dermatitis

China
Actelion

Completed

A Study of Selexipag in Healthy Male Participant

Healthy

Belgium
Azurity Pharmaceuticals

Completed

An Abuse Potential Study of Orally Administered HORIZANT in Healthy, Non-dependent, Recreational Drug Users

Abuse Potential

United States
Heptares Therapeutics Limited
Quotient Clinical

Completed

Relative Bioavailability Study in Healthy Subjects to Evaluate the Pharmacokinetics of HTL0009936 After One Dose of Prototype Formulation

Alzheimer's Disease

United Kingdom
GlaxoSmithKline
Quotient Clinical

Completed

A Study to Compare the Pharmacokinetics (PK) of GSK2982772 Following Administration of Different Modified Release (MR) Formulations in Capsule and MR Tablet Formulations Relative to an Immediate Release (IR) Tablet Formulation and to Check the PK of MR Formulation in Capsule Following Repeat Doses

Autoimmune Diseases

United Kingdom
GlaxoSmithKline
Quotient Sciences

Completed

A Study to Investigate the Pharmacokinetics (PK) of Modified Release (MR) Prototype Coated Tablet Formulations of GSK2982772

Autoimmune Diseases

United Kingdom
Boehringer Ingelheim

Completed

A Phase I Multiple Dose Pharmacokinetic Study of Nevirapine Extended Release (XR) in HIV-1 Infected Children.

HIV Infections

United States, Botswana, Germany, South Africa
Pfizer

Completed

A Study to Evaluate the Study Medication (Etrasimod) When Mixed With Food in Healthy Participants

Healthy Participants

Belgium
Pfizer

Completed

A Study To Evaluate Different Formulations Of PF-06865571 In Healthy Subjects

Healthy

Belgium
AstraZeneca

Completed

SR-Registration Study 1, ROW: Efficacy and Safety of Seroquel® in the Treatment of Patients With Schizophrenia

Schizophrenic Disorder

Bulgaria, Russian Federation, Romania, South Africa, Greece, Philippines, India, Indonesia
AstraZeneca

Completed

Study Comparing the Tolerability of Seroquel IR With Seroquel XR in Patients With Bipolar Depression

Bipolar Depression
Mundipharma Research Limited

Terminated

A Study Assessing the Efficacy and Safety of Lodotra® Compared to Prednisone IR in Subjects Suffering From PMR

Polymyalgia Rheumatica

United Kingdom
Dinora, Inc.
PharPoint Research, Inc.; Analgesic Solutions

Terminated

Delayed Release Prednisone in PMR

Polymyalgia Rheumatica

United States
AstraZeneca

Terminated

Rapid Versus Conventional Titration of Quetiapine in Schizophrenia/Schizoaffective Disorder (RAPID)

Psychotic Disorders | Schizophrenia | Schizoaffective Disorders

United Kingdom
GlaxoSmithKline

Completed

A Study to Compare the Safety and Drug Levels in Blood When Using Various Forms of GSK189075 Given to Healthy Subjects

Diabetes Mellitus, Type 2 | Type 2 Diabetes Mellitus

United States
Pfizer

Completed

Relative Bioavailability Study of a Modified-Release Formulation of PF-06865571 in Healthy Adult Participants

Healthy Participants

Belgium
Pfizer

Completed

A Single Dose Crossover Study In Healthy Subjects To Evaluate Different Formulations Of PF-06882961

Healthy Subjects

United States
GlaxoSmithKline

Completed

First-Time-in-Humans Study to Assess Safety, Pharmacokinetics & Pharmacodynamics of SB756050

Diabetes Mellitus, Type 2

United States
AstraZeneca

Completed

Rapid Dose Escalation of Quetiapine Versus Conventional Escalation in Acute Schizophrenic Patients

Schizophrenia

Germany
Janssen Research & Development, LLC

Completed

Bioequivalence Study of Metformin Component of Canagliflozin and Metformin Fixed Dose Combination Immediate Release (IR) Tablet Comparing With Metformin IR Tablet Co-administered With Canagliflozin Tablet in Healthy Fed and Fasted Participants

Healthy

United States
Astellas Pharma Europe B.V.

Completed

A Study to Compare the Actions in the Body of Healthy Subjects of Three Modified Release Formulations of YM178 Under Fasted and Fed Conditions With One Immediate Release Formulation of YM178 Under Fasted Conditions

Healthy Subjects | Pharmacokinetics of YM178

Netherlands
GlaxoSmithKline

Completed

Clinical Evaluation of Ropinirole CR-RLS ( SK&F101468)Tablets in Restless Legs Syndrome

Restless Legs Syndrome

Japan
Alza Corporation, DE, USA

Completed

A Study on Efficacy (Effectiveness), Safety, and Impact on Quality of Life Measures of Dilaudid CR (Controlled Release);, Hydromorphone HCl in Patients With Chronic Low Back Pain

Low Back Pain
AstraZeneca

Terminated

Study of Saxagliptin, 5-Hydroxy Saxagliptin, and Metformin Concentrations/Levels in Pediatric Subjects With T2DM

Type 2 Diabetes Mellitus

United States
Janssen Research & Development, LLC

Completed

Bioequivalence Study of Metformin Component of Fixed Dose Combination (FDC) Immediate Release (IR) Tablet of Canagliflozin and Metformin Compared to Metformin IR Tablet Co-administered With Canagliflozin in Healthy Fed and Fasted Participants

Bioequivalence

United States
Pfizer
ViiV Healthcare

Completed

Study to Estimate the Pharmacokinetics, Bioavailability and Effect of Food on Single Dose Modified-release Lersivirine 500 mg in Healthy Subjects

Healthy Volunteer

Belgium
ApoPharma

Completed

Comparison of Deferiprone Extended Release Tablets and Ferriprox Immediate Release Tablets in Healthy Volunteers

Healthy

Canada
GlaxoSmithKline

Completed

Clinical Evaluation of Ropinirole PR/XR Tablets in Monotherapy for Parkinson's Disease (PD)

Parkinson Disease

Japan
GlaxoSmithKline

Completed

Ropinirole XR (Extended Release) In Patients With Restless Legs Syndrome

Restless Legs Syndrome

United States, Canada
Ensysce Biosciences

Completed

A Study to Evaluate the Intranasal Abuse Potential of PF614 in Non-Dependent Recreational Opioid Users

Recreational Drug Use

United States
GlaxoSmithKline

Completed

RLS In Adults: Comparing Immediate Release Formulation With Extended Release Formulation Of Ropinirole

Restless Legs Syndrome | Restless Legs Syndrome (RLS)

Spain, United States, Belgium, Sweden, Australia, Netherlands, United Kingdom, Italy, Austria, Germany, Denmark, France, Norway
Boehringer Ingelheim

Completed

Pramipexole Pilot Phase II Study in Children and Adolescents With Tourette Disorder According to DSM-IV Criteria

Tourette Syndrome

United States, Germany
GlaxoSmithKline

Completed

Long-Term Safety Of Ropinirole XR In Patients With Restless Legs Syndrome

Restless Legs Syndrome

United States, Canada
Roy D. Bloom, MD
Veloxis Pharmaceuticals

Recruiting

Pulse Wave Velocity, Tacrolimus Time in Therapeutic Range and CV in African American Kidney Transplants (PTAAK)

Kidney Transplant; Complications

United States
Sarfez Pharmaceuticals, Inc.

Recruiting

Effect of Extended Release Torsemide in Patients With Congestive Heart Failure and Overactive Bladder

Heart Failure | Overactive Bladder | Incontinence

United States
Boehringer Ingelheim

Completed

Bioavailability of Different Pramipexole Slow-release Formulations Compared to Immediate-release Tablet in Healthy Male Volunteers

Healthy
Seoul National University Hospital

Completed

Study to Compare the Effect of Ropinirole Prolonged Release Once-daily Versus Twice-daily

Parkinson Disease

Korea, Republic of
GlaxoSmithKline

Completed

Healthy Volunteer Study Using 3 Different Formulations of Firategrast

Multiple Sclerosis, Relapsing-Remitting

Australia
Desitin Arzneimittel GmbH
FGK Clinical Research GmbH

Terminated

EXTENT: EXtended Tolerability and Efficacy of a Novel Formulation of Oxcarbazepine in a Trial in Partial Epilepsy

Partial Epilepsy

Germany

3

Subscribe